

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant

John L. Magnani et al.

Application No.

10/601,080

Filed

June 19, 2003

For

COMPOSITIONS AND METHODS FOR DIAGNOSIS AND

THERAPY OF MEDICAL CONDITIONS INVOLVING

ANGIOGENESIS

Art Unit

: 1645

Docket No.

400068.413

Date

: January 13, 2004

Mail Stop Missing Parts Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

INFORMATION DISCLOSURE STATEMENT

Commissioner for Patents:

In accordance with 37 C.F.R. §§ 1.56 and 1.97 through 1.98, Applicants wish to make known to the U.S. Patent and Trademark Office the references set forth on the attached form PTO-1449 (copies and/or cover pages of the cited references are enclosed). As to any reference supplied, Applicants do not admit that it is "prior art" under 35 U.S.C. §§ 102 or 103, and specifically reserve the right to traverse or antedate any such reference, as by a showing under 37 C.F.R. § 1.131 or other method. Although the aforesaid references are made known to the Patent and Trademark Office in compliance with Applicants' duty to disclose all information that they aware of which is believed relevant to the examination of the above-identified application, Applicant believe that their invention is patentable.

Due to the prohibitive amount of paper, Applicants note that only cover pages to U.S. Patents and Published U.S. Applications have been provided at this time. If the Examiner so wishes, full copies will be provided.

Please acknowledge receipt of this Information Disclosure Statement and kindly make the cited references of record in the above-identified application.

Respectfully submitted,
Seed Intellectual Property Law Group PLLC

Richard G. Sharkey, Ph.D. Registration No. 32,629

Enclosures:

Form PTO-1449 (17 Sheets) Cited References (118) other than U.S. Patents & Published U.S. Applications Cover Pages of 121 cited U.S. Patents & Published U.S. Applications

\446815

LawrenceT/446815

Sheet <u>1</u> of <u>17</u>

FORM PTO-1449 (REV.7-80)			DEPARTMENT OF ENT AND TRADEN	į į		APPLICATION NO. $10/601.080$	10/601,080 OIPE		
					APPLICANTS		1 10/001,009		2005 2005
INFO)RMA	ATION DISCLOSUI		ENT	John L. Magnani et	al	9	IAN 1 3	2004 K
		(Use several sheets if nece	essary) -		FILING DATE June 19, 2003		GROUP ART WIT		2 004 #
	,		***	85 A (83 E3 5 1/83)	<u> </u>		1043	RADEM	ARKO
*EXAMINER	— Т	·		PATENT	DOCUMENTS	Ι		FILING	DATE
INITIAL		DOCUMENT NUMBER	DATE		NAME	CLA		IF APPRO	
	AA	4,471,057	9/11/84	Koprowsł	· • ·	436	518		
	AB	4,851,511	7/1989	Hakomor	i et al.	530	387		
	AC	4,859,769	8/22/89	Karlsson	et al	536	53		
	AD	4,876,199	10/24/89	Hakomor	i	530	387		
	AE	4,925,796	5/1990	Bergh et a	al.	435	97	ļ	
	AF	4,946,830	08/1990	Pulverer e	et al.				-
	AG	5,143,712	09/01/92	Brandley	et al.	424	1.1		
	АН	5,151,360	09/29/92	Handa et	al.	435	240.2		
	Αl	5,211,937	5/18/93	Brandley	et al.	424	1.1		
	AJ	5,268,364	12/07/93	Kojima et	Kojima et al. 514 25				
			FOREI	GN PATEN	NT DOCUMENTS				
		DOCUMENT NUMBER	DATE		COUNTRY			TRANSI	ATION NO
	AK #	EP 319253 A2	06/07/89	EPO					
	AL !	EP 381 310 A1	08/08/90	EPO					
	AM	EP 408 859 A2	1/23/91	EPO					
	AN	EP 671407 A2	09/13/95	EPO					
	AO	WO 90/13300	11/15/90	WIPO			-		
		ОТНЕ	R PRIOR A	RT (Including	Author, Title, Date, Pertinent P	ages, Etc.)		
	AP				ockade Prevents Antig siveness in Allergic S				40
		Med. 159: 12	05-1214, 19	99.			<u> </u>		
	AQ				Characterization of a the Carcinoma-association				reted
					em. 266(32):21537-21 Antagonists," <i>Helvet</i>			11). 28	93-
	AR	2907, 2000.							
EXAMINE	AMINER				DATE CONSIDERED				
* EXAMINE					nformance with MPEP 609. Drawith next communication to ann		ough citation if not ir	1	

ATTY. DOCKET NO. APPLICATION NO. U.S. DEPARTMENT OF COMMERCE (REV.7-80) PATENT AND TRADEMARK OFFICE 400068.413 10/601,080 APPLICANTS John L. Magnani et al INFORMATION DISCLOSURE STATEMENT GROUP ART UNIT (Use several sheets if necessary) FILING DATE JAN 1 3 2004 June 19, 2003 1645 U.S. PATENT DOCUMENTS BADENS *EXAMINER FILING DATE DOCUMENT NUMBER DATE NAME CLASS SUBCLASS INITIAL IF APPROPRIATE 5,304,640 04/19/94 Lasky et al. 536 23.5 BA Venot et al. 514 54 5,352,670 10/04/94 BB 5,369,096 11/29/94 Yamada et al. 514 61 BC 552 290 BD 5,412,123 05/02/95 Rao et al. 514 25 5,444,050 08/22/95 Kogan et al. BE 5,464,778 11/07/95 Cummings et al. 436 503 BF 8 5,464,815 11/07/95 Chamow et al. 514 BG 5,470,843 11/28/95 Stahl et al. 514 61 530 387.3 Bl 5,484,891 01/16/96 Lasky et al. 514 460 5,486,536 01/23/96 Ward et al. BJ FOREIGN PATENT DOCUMENTS DOCUMENT TRANSLATION DATE COUNTRY NUMBER YES NO BK WO 91/19502 12/26/91 WIPO BL WO 92/01718 2/6/92 **WIPO** BM WO 92/07572 5/14/92 WIPO BN WO 94/26760 11/1994 **WIPO** BO WO 94/29477 12/1994 **WIPO** OTHER PRIOR ART (Including Author, Title, Date, Pertinent Pages, Etc.) Berg et al., "A Carbohydrate Domain Common to Both Sialyl Lea and Sialyl Lex Is BP Recognized by the Endothelial Cell Leukocyte Adhesion Molecule ELAM-1," J. Biol. Chem. 266(23):14869-14872, 1991. Berg et al., "The Cutaneous Lymphocyte Antigen Is a Skin Lymphocyte Homing Receptor во for the Vascular Lectin Endothelial Cell-Leukocyte Adhesion Molecule 1," J. Exp. Med. 174:1461-1466, 1991. Bird and Kimber, "Oligosaccharides Containing Fucose Linked α(1-3) and α(1-4) to N-BR Acetylglucosamine Cause Decompaction of Mouse Morulae," Devel. Biol. 104:449-460, 1984. **EXAMINER** DATE CONSIDERED * EXAMINER: Initial if reference considered, whether or not criteria is in conformance with MPEP 609. Draw line through citation if not in

conformance and not considered. Include copy of this form with next communication to applicant(s).

Sheet 3 of 17

FORM PTO-1449 (REV.7-80))		DEPARTMENT OF ENT AND TRADEN		ATTY. DOCKET NO. 400068.413		APPLIC	ATION NO. 01,080	OIP	E
					APPLICANTS					7
INFO	ORM.	ATION DISCLOSU		ENT	John L. Magnani et a	<u> </u>		— h	JAN 1	3 7004
		(Use several sheets if nec	essary)		FILING DATE			ART UN		
					June 19, 2003		1645	H.	\	
*CV AMDICD			U.S.	PATENT I	DOCUMENTS				* TBAD	
*EXAMINER INITIAL		DOCUMENT NUMBER	DATE	-	NAME	CLA	ss	SUBCLASS	FILING IF APPRO	
	CA	5,519,008	05/21/96	Rao et al.		514	1	26		
	СВ	5,527,785	06/18/96	Bevilacqu	a et al.	514		56		
	СС	5,538,724	07/1996	Butcher et	t al.	424		152.1		
	CD	5,559,103	09/24/96	Gaeta et a	1.	514		54		
	CE	5,576,305	11/19/96	Ratcliffe		514		25		
	CF	5,580,858	12/03/96	Ippolito et	t al.	514		25		
	CG	5,580,862	12/03/96	Rosen et a	ıl.	514		61		
	СН	5,589,465	12/31/96	Ishida et a	1.	514		25		
	CI	5,604,207	02/18/97	DeFrees et al. 514			25			
	CJ	5,618,785	04/08/97	Heavner e	et al.	514		2 .		
			FOREI	GN PATEN	T DOCUMENTS					
-		DOCUMENT NUMBER	DATE		COUNTRY				TRANSL	.ATION NO
	СК	WO 95/03059	02/02/95	WIPO						
	CL	WO 95/29681	11/09/95	WIPO						
	СМ	WO 96/20204	07/04/96	WIPO		V-18				
	CN	WO 96/25418	08/22/96	WIPO						
	со	WO 96/26950	09/06/96	WIPO			-			
	<u>L</u>	ОТНЕ	R PRIOR A	RT (Including	Author, Title, Date, Pertinent Pa	ges, Etc.,)			
		Biercke, J., "	Rational De	sign and Sy	nthesis of Oligosaccha	ride N	// // // // // // // // // // // // //	ics: Sele	ctin	
	СР	Antagonists a	as Cell Adhe erican Chen	esion Inhibi nical Societ	tors," <i>Abstracts of Pap</i> y, Chicago, IL, August	ers, 2 : 20-2	10 th A 4, 199	<i>CS Natio</i> 5. MEDI	nal -18.	
	CQ	Bowen et al.,	"Characteri	zation of a	Human Homologue of	the N	1urine	Peripher	ral Lym	ph
	CR	Brandley et a	I., "Carbohy	drate Ligar	nal of Cell Biology 109:421-427, 1989. Ligands of LEC Cell Adhesion Molecules," Cell 63:861-					
EXAMINE		863, 1990.			DATE CONSIDERED					
					<u>.</u>					
* EXAMINI					nformance with MPEP 609. Draw with next communication to applic		ough cita	tion if not in		

Sheet <u>4</u> of <u>17</u>

FORM PTO-1449 U.S. DEPARTMENT OF COMME (REV.7-80) PATENT AND TRADEMARK OF										
					APPLICANTS					
INFO	ORM.	ATION DISCLOSU	RE STATEM	ENT	John L. Magnani et a	l				
		(Use several sheets if nec	essary)		FILING DATE		GROUP ART	UNIT		
					June 19, 2003		1645			
			U.S.	PATENT	DOCUMENTS					
*EXAMINER INITIAL		DOCUMENT NUMBER	DATE		NAME	CLA	SS SUB	CLASS	FILING IF APPRO	
	DA	5,622,937	04/22/97	Kogan et		514	25			
	DB	5,639,734	06/17/97	Esko et al	. JAN 1 3 2004 H	514	25			
- <u>-</u> .	DC	5,646,123	07/08/97	Ippolito e	t al.	514	25			
	DD	5,646,248	07/08/97	Sawada e	t al. PADEMARK	530	350)		
	DE	5,648,344	07/15/97	Brandley	et al.	514	61			
	DF	5,654,282	08/05/97	Tang et al		514	25			
	DG	5,654,412	08/05/97	Srivastava	a et al.	536	18.	5		
	DH	5,658,880	08/19/97	Dasgupta	et al.	514	8			
	DI	5,663,151	09/02/97	Martel et	al.	514	25			
	DJ	5,679,321	10/21/97	Dasgupta	et al.	424	9.1			
			FOREI	GN PATEN	NT DOCUMENTS		·			
		DOCUMENT NUMBER	DATE		COUNTRY			-	TRANSI YES	ATION NO
	DK	WO 97/01335	01/16/97	WIPO						
	DL	WO 97/14707	04/24/97	WIPO						
	DM	WO 97/28173	08/07/97	WIPO						
	DN	WO 97/28174	08/07/97	WIPO						
	DO	WO 99/43353	09/02/99	WIPO				=		
		ОТНЕ	ER PRIOR A	RT (Including	Author, Title, Date, Pertinent Pa	ges, Etc.,)			
	DP				ne on a Glycoprotein Si em. 54:388-394, 1990.	ialyltr	ansferase	Activi	ty in (26
	DQ	Childs et al.,	"High-mole	cular-weigl	ht glycoproteins are the	majo	r carriers	of the	11 "	
		Biochem, J. 2	2 <i>15</i> :491-503	, 1983.	s I, i and SSEA-1 of mo					j
	DR		hesive Intera		ic Acid on Neutrophils Activated Platelets," B					
EXAMINE					DATE CONSIDERED					
* EXAMIN					nformance with MPEP 609. Draw with next communication to applic		ough citation	if not in		

FORM PTO-1449 (REV.7-80)	1		DEPARTMENT OF ENT AND TRADEM	Ŧ						
(,					APPLICANTS		10/0	501,080		
INFO)RM.	ATION DISCLOSUI	RE STATEM	ENT	John L. Magnani et a	1				_
		(Use several sheets if nece	essary)		FILING DATE			JP ART UNIT	-	
					June 19, 2003		164	.5		
			U.S.	PATENT 1	DOCUMENTS					
*EXAMINER INITIAL		DOCUMENT NUMBER	DATE		NAME PE	CLA	ss	SUBCLASS	FILINC IF APPRO	DATE OPRIATE
	EA	5,679,644	10/21/97	Rao et al.	The state of the s	514	<u> </u>	26		
	ЕВ	5,686,426	11/11/97	Martel et		514		25		
	EC	5,693,621	12/02/97	Toepfer e	t al. TRADEMARK	514		25		
	ED	5,695,752	12/09/97	Rosen et a	al.	424		94.61		
	EE	5,710,023	01/20/98	Collins et	al.	435		69.1		
	EF	5,710,123	01/20/98	Heavner e	et al.	514		2		
	EG	5,723,583	03/03/98	Seed et al		530		387.3		
	ЕН	5,728,685	03/17/98	Abbas et a	al.	514		53		
	El	5,739,300	04/14/98	Toepfer e	t al.	536		4.1		
	EJ	5,747,463	05/05/98	Marinier o	et al.	514		25		
			FOREI	GN PATEN	NT DOCUMENTS					
		DOCUMENT NUMBER	DATE		COUNTRY				TRANS YES	NO
	EK	WO 02/22820	03/21/02	WIPO						
	EK EL	WO 02/22820 8 WO 02/062810	03/21/02 08/15/02	WIPO WIPO						
		 								
	EL	 								
	EL EM	 								
	EL EM EN	WO 02/062810	08/15/02	WIPO	Author, Title, Date, Pertinent Pa	ges, Eic.,				
	EL EM EN EO	WO 02/062810 OTHE Datta and Tal	08/15/02 R PRIOR A cayama, "Iso	WIPO RT (Including plation and	Author, Title. Date. Pertinent Pa	se 6-m	ono-			
	EL EM EN	OTHE Datta and Tak corynomycola NMR," Carbo	R PRIOR A kayama, "Iso ates from Co ohydrate Re	RT (Including plation and prnyebacted search 245	purification of trehalogrium matruchotii. Stru 5: 151-158, 1993.	se 6-m ctural	ono- char	acterizatio	on of ¹ H	
	EL EM EN EO	OTHE Datta and Tak corynomycola NMR," Carbe Duijvestijn et	R PRIOR A cayama, "Iscates from Coohydrate Re al., "High I	RT (Including plation and prnyebacted search 245)	purification of trehalogerium matruchotii. Strub: 151-158, 1993. Differentiation in Hun	se 6-m ctural	ono- char mph	acterization	n of ¹ l iflamm	atory
	EL EM EN EO	Datta and Talcorynomycola NMR," Carbo Duijvestijn et Tissues Defin Dupré, B. et a	R PRIOR A cayama, "Iscates from Coohydrate Refal., "High Indeed by Mondal., "Glycomosyloxy)met	RT (Including plation and prnyebacters search 245 Endothelial pelonal Antimetic Selections)	purification of trehalogrium matruchotii. Stru 5: 151-158, 1993.	se 6-m ctural nan Ly n. J. P	ono- char mph ath.	acterizationoid and In 130:147-1	on of ¹ l iflamm 55, 198	atory 38.
EXAMINE	EL EM EN EO EP EQ ER	Datta and Take corynomycola NMR," Carbe Duijvestijn et Tissues Defin Dupré, B. et a Mannopyrand	R PRIOR A cayama, "Iscates from Coohydrate Refal., "High Indeed by Mondal., "Glycomosyloxy)met	RT (Including plation and prnyebacters search 245 Endothelial pelonal Antimetic Selections)	purification of trehalogerium matruchotii. Struff: 151-158, 1993. Differentiation in Hundribody HECA-452," Anaectin Inhibitors: (α-D-	se 6-m ctural nan Ly n. J. P	ono- char mph ath.	acterizationoid and In 130:147-1	on of ¹ l iflamm 55, 198	atory 38.

FORM PTO-1449 ATTY. DOCKET NO. APPLICATION NO. U.S. DEPARTMENT OF COMMERCE (REV.7-80) PATENT AND TRADEMARK OFFICE 400068.413 10/601.080 APPLICANTS John L. Magnani et al INFORMATION DISCLOSURE STATEMENT (Use several sheets if necessary) FILING DATE GROUP ART UNIT June 19, 2003 1645 U.S. PATENT DOCUMENTS *EXAMINER FILING DATE DOCUMENT NUMBER DATE NAME CLASS SUBCLASS INITIAL IF APPROPRIATE 5,750,508 05/12/98 Dasgupta et al. 514 25 FΑ 05/19/98 Heavner et al 514 9 5,753,617 FB JAN 1 3 2004 5,753,631 05/19/98 Paulson et al 514 25 FC 06/09/98 Numata et al. 514 25 FD 5,763,413 RADEMAR 5 06/09/98 Rao et al. 536 5,763,582 FΕ 25 5,789,385 08/04/98 Anderson et al. 514 FF 08/04/98 Baker et al. 536 24.5 5,789,573 FG 5,795,958 08/18/98 Rao et al. 530 331 25 09/22/98 514 FΙ 5,811,404 De Frees et al. 25 09/22/98 514 5,811,405 Toepfer et al. ΕJ 328 10/06/98 Toepfer et al. 528 5,817,742 FΚ 2 5,827,817 10/27/98 Larsen et al. 514 FL 10/27/98 514 103 5,827,837 Bevilacqua et al. FM 23 11/03/98 Wong et al. 514 5,830,871 FOREIGN PATENT DOCUMENTS TRANSLATION DOCUMENT DATE NUMBER YES FO OTHER PRIOR ART (Including Author, Title, Date, Pertinent Pages, Etc.) Edgington, "How Sweet It Is: Selectin-Mediating Drugs," Biotechnology 10: 383-389, FΡ 1992. Eggens et al., "A Role of Carbohydrate-Carbohydrate Interaction in the Process of Specific FO Cell Recognition During Embryogenesis and Organogenesis: A Preliminary Note," Biochem. Biophys. Res. Commun. 158(3):913-920, 1989. Eggens et al., "Specific Interaction between Le^X and Le^X Determinants. A Possible Basis FR for Cell Recognition in Preimplantation Embryos and in Embryonal Carcinoma Cells," J. Biol. Chem. 264(16):9476-9484, 1989. **EXAMINER** DATE CONSIDERED * EXAMINER: Initial if reference considered, whether or not criteria is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant(s).

Sheet <u>7</u> of <u>17</u>

FORM PTO-1449 U.S. DEPARTMENT OF CO (REV.7-80) PATENT AND TRADEMAR									
					APPLICANTS				
INFO	ORM.	ATION DISCLOSU	RE STATEM	ENT	John L. Magnani et a	<u> </u>		_	
		(Use several sheets if nec	essary)		FILING DATE		GROUP ART UNIT		
					June 19, 2003		1645	· · · · · · · · · · · · · · · · · · ·	
			U.S.	PATENT I	DOCUMENTS	-			
*EXAMINER INITIAL		DOCUMENT NUMBER	DATE		NAME	CLA	SS SUBCLASS	FILING IF APPRO	
	GA	5,837,689	11/17/98	Anderson	et al. OVPE	514	25	_	
	GB	5,837,690	11/17/98	Rao et al.	2 2004 円	514	26		
	GC	5,840,679	11/24/98	Larsen et	al.	514	8	ļ	
	GD	5,854,218	12/29/98	DeFrees	al. TRADEMARK	514	25		
	GE	5,858,983	01/12/99	Seed et al		514	23		
	GF	5,858,994	01/12/99	Kretzschn	nar et al.	514	62		
	GG	5,880,091	03/09/99	Cumming	s et al.	514	8		··
	GH	5,916,910	06/29/99	Lai		514	423	ļ	
	GI	5,919,768 07/06/99 Korga			al.	514	25		
	GJ	5,919,769	07/06/99	Tsukida e	t al.	514	25		
	GK	5,962,422	10/05/99	Nagy et al		514	25		
	GL	5,976,540	11/02/99	Rittershau	s et al.	424	184.1	ļ	
	GM	5,977,080	11/02/99	Rosen et a	ıl.	514	25		
	GN	5,985,852	11/16/99	Nagy et al		514	54		
			FOREI	GN PATEN	T DOCUMENTS				
		DOCUMENT	DATE		COUNTRY			TRANSI	
	GO	NUMBER						YES	NO
									
	-				Author, Title, Date, Pertinent Pag				
	GP	Glycoconjug			lonor specificity of glyon, 1999.	cosyl	transferases,"		
					to-N-Fucopenataose II				
	GQ	Ineffective,"	J. Exp. Med	. <i>160</i> :1591-	Embryos, While the F 1596, 1984.			is	
	GR	Fenderson et	al., "Coordi	Exp. Med. 160:1591-1596, 1984. , "Coordinate Expression of X and Y Haptens during" Devel. Biol. 114:12-21, 1986.			ring Murine		
EXAMINE	R	1	-, -		DATE CONSIDERED		 "		
* EXAMINI	ER:	Initial if reference consider	red, whether or no	criteria is in conformance with MPEP 609. Draw line through citation if not in					
2.1					with next communication to applic				

		7 NO. E 7 330032030						5 01 17	
FORM PTO-1449 (REV.7-80))		DEPARTMENT OF ENT AND TRADEM		400068.413		10/601,080		
					APPLICANTS				
INFO	ORM.	ATION DISCLOSU	RE STATEM	ENT	John L. Magnani et a	1			
		(Use several sheets if nec	essary)		FILING DATE		GROUP ART UN	IT	
			, <u>-</u>		June 19, 2003		1645		
	•	 	U.S.	PATENT	DOCUMENTS				
*EXAMINER INITIAL		DOCUMENT NUMBER	DATE		NAME	CLA	SS SUBCLA		G DATE ROPRIATE
	НА	5,994,402	11/30/99	Rotstein e		514	547		
	нв	6,001,819	12/14/99	Simon et	al. (2004 W	514	54		
	нс	6,001,988	12/14/99	Parma et a		536	24.3		
	НD	6,033,665	03/07/00	Yednock	et al. FADEMARK	424	130.1		
	HE	6,037,333	03/14/00	Panjwani		514	62		
	HF	6,110,897	08/29/00	Unverzag	t et al.	514	25		
	НG	6,111,065	08/29/00	Heavner e	et al.	530	300		
	НН	6,177,547	01/23/01	Cumming	s et al.	530	388.22	2	
	ні 6,121,233 09/19/00 Magna				agnani et al. 51		8		
	нл	6,124,267	09/26/00	Mc Ever	et al.	514	25		
	нк	6,133,239	10/17/00	Handa et	al.	514	25		
	HL :	6,133,240	10/17/00	Taylor et	al.	514	25		
	НМ	6,136,790	10/24/00	Toepfer e	t al.	514	25		
	HN	6,169,077	01/02/01	Oehrlein		514	25		
			FOREI	GN PATEN	NT DOCUMENTS				
		DOCUMENT	DATE		COUNTRY				SLATION
		NUMBER					-	YES	NO
	НО	L			· · · · · · · · · · · · · · · · · · ·				<u> </u>
					Author, Title, Date, Pertinent Pa				
	НР				antigen defined by mo urine embryogenesis,"				3,
	НQ	Fukushi et al Isolation of I	Hybridoma <i>A</i>	antibodies [ccumulating in Human That Differentially Rec	ogniz	e Mono-, Di	II. Sele	ctive
					ol. Chem. 259(7):4681-			ΙΙΙ Δ	
	HR	Hybridoma A	Antibody (FE	vel Fucolipids Accumulating in Human Adenocarcinoma. In the Indiana Adenocarcinoma of the Indiana Paragraphica (Indiana Paragraphica					;
EXAMINE	R			· <u>· · · · · · · · · · · · · · · · · · </u>	DATE CONSIDERED				
* EXAMINI					nformance with MPEP 609. Draw		ough citation if no	ot in	
		conformance and not cons							

Sheet <u>9</u> of <u>17</u>

FORM PTO-144		L NO. EV336652038	DEPARTMENT OF	COMMERCE	Sheet 9 of 17 MMERCE ATTY, DOCKET NO. APPLICATION NO.				
REV.7-80)	,		ENT AND TRADE						
					APPLICANTS				
INF	ORM	ATION DISCLOSU	RE STATEM	ENT	John L. Magnani et	al			
		(Use several sheets if neo	cessary)		FILING DATE		GROUP ART UNIT		
					June 19, 2003		1645		
			U.S	. PATENT	DOCUMENTS				
*EXAMINER INITIAL		DOCUMENT NUMBER	DATE		NAME PE VO	CLA	ASS SUBCLASS		G DATE OPRIATI
,	IA	6,187,754	02/13/01	Oehrlein	The same of the sa	514	25		
	ΙB	6,193,973	02/27/01	Tuttle	NAN 1 3 2004 H	424	195.1		
	IC	6,193,979	02/27/01	Rittershau	is et al.	424	195.11		
	ID	6,197,752	03/06/01	Schmidt 6	et al.	514	23		
	ΙE	6,225,071	05/01/01	Cumming	gs et al.	435	7.24		
	IF	6,235,309	05/22/01	Nagy et a	<u>.</u>	424	450		
	IG	6,280,932	08/28/01	Parma et	al	435	6		
	н	6,309,639	10/30/01	Cumming	gs et al.	424	143.1		
	П	6,387,884	05/14/02	Magnani	et al.	514	25		
	IJ	6,391,857	05/21/02	Magnani	et al.	514	25		
	ıк	6,407,135	06/18/02	Lai et al.		514	423		
	IL	6,465,434	10/15/02	Magnani	et al.	514	23		
	IM	6,492,332	10/10/02	Demopul	os et al.	514	12		
	IN	6,503,885	01/07/03	Kiso et al	•	514	25		
			FORE	IGN PATE	NT DOCUMENTS				
		DOCUMENT NUMBER	DATE		COUNTRY			TRANS YES	LATION
	Ю								
	•	ОТН	ER PRIOR A	RT (Including	Author, Title, Date, Pertinent	Pages, Etc	.)		
	ΙP	Gabius et al. 6:573-578, 1	, "Endogeno 986.	ous Tumor I	Lectins: Overview and	l Persp	ectives," Antic	cancer I	Res.
	IQ	Gallatin et al	l., "A cell-su s." <i>Nature 3</i>	04:30-34, 1	cule involved in organ 983.	-			
	IR	Gooi et al., " group chains	Stage-specif	fic embryor	iic antigen involves α	$1 \rightarrow 3$	fucosylated ty	ype 2 bl	ood
EXAMINI	ER				DATE CONSIDERED				
* EXAMIN	ER:	Initial if reference conside	red, whether or no	ot criteria is in co	nformance with MPEP 609. Di	aw line th	rough citation if not	in	_

Sheet 10 of 17

FORM PTO-1449 (REV.7-80)	•		DEPARTMENT OF ENT AND TRADEM						
					APPLICANTS			•	
INFO	DRM.	ATION DISCLOSU	RE STATEM	ENT	John L. Magnani et al				
		(Use several sheets if nec	essary)		FILING DATE		GROUP ART UNIT		
···					June 19, 2003		1645		
			U.S.	PATENT 1	DOCUMENTS				
*EXAMINER INITIAL		DOCUMENT NUMBER	DATE		NAME PE	CLA	SS SUBCLASS		DATE OPRIATE
	JA	6,528,487	03/04/03	Heavner e	10	514	13		
	JB	2001/0046970	11/29/01	Nagy et al	I. JAN 1 3 2004	514	53	 -	
	JC	2001/0051370	12/13/01	Bistrup et	al. RADEMARKS et al.	435	193		
	JD	2002/0026033	02/28/02	Cumming	s et al.	530	322	_	
	JE	2002/0028205	03/07/02	Holgersso	on et al.	424	184.1		
	JF	2002/0031508	03/14/02	Wagner e	t al.	424	94.63		
	JG	2002/0040008	04/04/02	Wagner e	t al.	514	41		
	JH	2002/0132220	09/19/02	Berens et	al.	435	1.1		
	JI	2002/0164336	11/07/02	Harrison e	et al.	424	146.1		
	IJ	2002/0164748	11/07/02	Bistrup et	al.	435	193		
	JK	2002/0168366	11/14/02	Stewart et	al.	424	146.1		
	JL	2003/0012787	01/16/03	Ashkenaz	i et al.	424	145.1		
	JM	2003/0012790	01/16/03	Ashkenaz	i et al.	424	178.1		
	JN	2003/0018181	01/23/03	Larsen et	al.	536	23.4		
			FOREI	GN PATEN	NT DOCUMENTS				
		DOCUMENT NUMBER	DATE		COUNTRY			TRANS YES	LATION NO
	JO								
		ОТНЕ	CR PRIOR A	RT (Including	Author, Title, Date, Pertinent Pag	ges Etc)	· !	1
	ID	Hakomori et	al., "Novel l	Fucolipids	Accumulating in Huma	n Ade	enocarcinoma.		
	JP	Glycolipids \ 1984.	With Di- or	Frifucosyla [.]	ted Type 2 Chain," J. B	Riol. C	Chem. 259(7):4	·672-46 	80,
	JQ				ture of a Developmenta uman Erythrocytes and				
					vs. Res. Comm. 100(4):			`	
	JR	Hakomori S.	, "Aberrant (Glycosylati	on in Cancer Cell Mem	brane	es as Focused of	on	
EXAMINE	R	1 1 Orycompida.	Overview at	ia i dispect	DATE CONSIDERED				
* EXAMINI	INER: Initial if reference considered, whether or not criteria is i				a is in conformance with MPEP 609. Draw line through citation if not in his form with next communication to applicant(s)				

Hynes, R., "Integrins: A Family of Cell Surface Receptors," Cell 48:549-554, 1987.

Itai, S. et al., "Differentiation-dependent Expression of I and Sialyl I Antigens in the

Issekutz, T., "Inhibition of in Vivo Lymphocyte Migration of Inflammation and Homing to

Lymphoid Tissues by the TA-2 Monoclonal Antibody. A Likely Role for VLA-4 in Vivo,"

Developing Lung of Human Embryos and in Lung Cancers," Cancer Research 50: 7603-

* EXAMINER: Initial if reference considered, whether or not criteria is in conformance with MPEP 609. Draw line through citation if not in

conformance and not considered. Include copy of this form with next communication to applicant(s).

Journal of Immunology 147:4178-4184, 1991.

KJ

KK

KL

* EXAMINER: Initial if reference considered, whether or not criteria is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant(s).

lines by cell fusion," Eur. J. Immunol. 6:511-519, 1976.

Köhler and Milstein, "Derivation of specific antibody-producing tissue culture and tumor

Kojima and Hakomori, "Specific Interaction between Gangliotriaosylceramide (G_{g3}) and

Koprowski et al., "Colorectal Carcinoma Antigens Detected by Hybridoma Antibodies,"

DATE CONSIDERED

Sialosyllactosylceramide (G_{M3}) as a Basis for Specific Cellular Recognition between Lymphoma and Melanoma Cells," *J. Biol. Chem. 264*(34):20159-20162, 1989.

specificity," Nature 256:495-497, 1975.

Somatic Cell Genetics 5(6):957-972, 1979.

LI

IJ

LK

LL

EXAMINER

FORM PTO-1449)		DEPARTMENT OF).			
(REV.7-80)		PAT	ENT AND TRADEN	MARK OFFICE	400068.413	10.	/601,080				
					APPLICANTS						
INFO	ORM.	ATION DISCLOSU		ENT	John L. Magnani et a	<u> </u>					
		(Use several sheets if nec	essary)		FILING DATE		OUP ART UNIT				
					June 19, 2003	16	45				
			U.S.	PATENT	DOCUMENTS						
*EXAMINER INITIAL		DOCUMENT NUMBER	DATE		NAME	CLASS	SUBCLASS		DATE OPRIATE		
	MA										
TPE	\		FOREI	GN PATE	NT DOCUMENTS		<u> </u>	·			
2	F)	DOCUMENT	DATE		COUNTRY			TRANS	LATION		
N 1 3 2004	<u> </u>	NUMBER						YES	NO		
1 ()	/мв										
RADEMARK				RT (Including	g Author, Title, Date, Pertinent Pa	ges, Etc.)					
					c Inhibitors of Selectin-	-Mediated	Cell Adhe	sion:			
	MC				ethylphenyl)-r- $(2-\alpha-D-$						
		monnopyrano	osyloxy)phe	nyl]hexane	(TBC1269)," J. Med. (Chem 41:	1099-1111,	1998.			
		Korgan, T.P.	et al., "Rati	onal Desig	n and Synthesis of Sma	Il Molecu	le. Non-				
	MD	oligosacchari	ide Selectin	Inhibitors:	rs: (α-D-Mannopyranosyloxy)biphenyl-Substituted						
		Corboxylic A	Acids," <i>J. Me</i>	ed. Chem	em. 38: 4976-4984, December 22, 1995.						
	ме	Kuzuoka, "A		civity of mu	rine monoclonal antibo	ody NCC-	ST-421," (Chem. A	4 <i>b</i> .		
				ructure Det	ermination of Five Sialyla	ated Oligo	saccharides	Derive	d		
	MF				of Patients Suffering from						
					$\alpha(1\rightarrow 3)$]GlcNAc $\beta(1\rightarrow \bullet)$						
					nal of Biological Chemis						
	MG	Larsen et al.,	"PADGEM" by a Lineage	-Dependen -Specific (t Adhesion of Platelets Carbohydrate, LNF III (to Monoc	cytes and N	eutrop	hils 200		
		Lindenberg e	et al "Carbo	hydrate bii	nding properties of mou	ise embry	os." <i>J. Ren</i> :	rod Fe	rt		
	МН	89:431-439,		any araco on			оо, о. пер.				
					de GM1 Reduces NMI	OA Neuro	toxicity in	Neonat	tal		
	MI				y 113:301-305, 1991.		• • •	1 .	<u> </u>		
	мл				ucosyltransferase cDN/						
		Trans. 19(3):			elial-leukocyte adhesio	n moiecu	ie i, Bioch	em. so	C.		
					Cell Adhesion to Vascu	lar Endoth	nelium Dete	ermine	d by		
	MK	a Transfected	d Human Fu	cosyltransf	erase cDNA," Cell 63:4	175-484, 1	990.		•		
	MI				ate, Differentiation Ant				f		
	ML				nized by Monoclonal Antibody VIM-2," Journal of						
EVAMINIT	D D	Biological C	nemistry 26.	5(21):1018):10186-10191, 1988.						
EXAMINE	ĸ				DATE CONSIDERED						
* EVAMINI	AINED: Initial if reference considered, whether or not criterio				informance with MDED 600. Drov	. U 4bb					

conformance and not considered. Include copy of this form with next communication to applicant(s).

Palcic et al., "A Bisubstrate Analog Inhibitor for α(1→2)-Fucosyltransferase," J. Biol. Chem. 264:17174-17181, 1989.

EXAMINER

DATE CONSIDERED

conformance and not considered. Include copy of this form with next communication to applicant(s)

NJ

NK

* EXAMINER:

1990.

Palcic et al., "Enzymic Synthesis of Oligosaccharides Terminating in the Tumor-

Palcic et al., "Regulation of N-Acetylglucosaminyltransferase V Activity. Kinetic Comparisons of

Parental, Rous Sarcoma Virus-Transformed BHK, and L-Phytohemagglutinin-Resistant BHK Cells Using Synthetic Substrates and an Inhibitory Substrate Analog," *J. Biol. Chem.* 265:6759-6769,

Associated Sialvl-Lewis-a Determinant," Carbohydr. Res. 190:1-11, 1989.

Initial if reference considered, whether or not criteria is in conformance with MPEP 609. Draw line through citation if not in

DAT KEDD	717 111	NO. E V 330032030		<u></u>	Sheet 13				
FORM PTO-144)		DEPARTMENT OF		ATTY, DOCKET NO.	APP	LICATION NO.		
(REV.7-80)		PATI	ENT AND TRADEM	IARK OFFICE	400068.413	10	/601,080		
					APPLICANTS				
INFO)RM	ATION DISCLOSUI	RESTATEM	ENT	John L. Magnani et	al			
11.12	J14 1,17	(Use several sheets if nece		2111	FILING DATE	1 .	OUP ART UNIT		
						16			
					June 19, 2003	10.	+3		
			U.S.	PATENT	DOCUMENTS				
*EXAMINER INITIAL		DOCUMENT NUMBER	DATE		NAME	CLASS	SUBCLASS		G DATE OPRIATE
	OA								
TPF			FOREI	GN PATEI	NT DOCUMENTS	1	1		
7.2		DOCUMENT						TRANS	LATION
	2\ 2\	NUMBER	DATE		COUNTRY			YES	NO
AN 1 3 2004	OB EON								
o 4	<i>y</i>	ОТНЕ	R PRIOR A	RT (Including	Author, Title, Date, Pertinent F	Pages, Etc.)			
THAILEMAN					Molecule Selectin Inhib		ts Against	Liver	-
	oc	Inflammators	Response	, Sillaii-N After Ische	mia and Reperfusion,	I Am Co	li Sura 18	25. 365	-372
		1997.	Response 1	Titol Isolio	ima and Reperrusion,	5. 11m. Co	ii. Durg. 10	5. 505	-372,
			"FLAM-1	Mediates (Cell Adhesion by Reco	ognition of	a Carbobyo	drate	
	OD	Ligand Sialy	l-Le ^X " <i>Scie</i>	nce 250:11	30-1132, 1990.	gintion of	a caroonye	iiuc	
		Picker et al	"The Neutro	phil Selec	tin LECAM-1 Present	s Carbohyo	lrate Ligan	ds to th	ne.
	OE	Vascular Sele	ectins ELAN	\tilde{A} -1 and GN	MP-140," Cell 66:921-	-933, 1991.			
	or	Prokazova et	al., "Sialyla	ted lactosy	Iceramides. Possible	inducers of	non-speci	fic	
	OF		ression and	atheroscler	otic lesions," Europea	an Journal	of Biochen	iistry I	<i>72</i> :1-
		6, 1988.							
	og	Rauvala et al.	., "Studies o	n Cell Adh	esion and Recognition	n. I. Exter	it and Spec	ificity	of
	00				ydrate-reactive Protein	ns (Glycosi	dases and	Lectins	i) and
		by Fibronecti							
	ОН	Rice and Bev	ilacqua, "Ai	n Inducible	Endothelial Cell Surf	face Glycor	protein Med	liates	
	OII				1303-1306, 1989.				
	OI	Ruoslahti and	l Pierschbac	her, "New	Perspectives in Cell A	Adhesion:	RGD and In	ntegrin	S,"
	OI	Science 238:4				 			
	OJ				clonal Antibody Reac				
	O,				the Body Fluid of Gas	strointestin	al Cancer I	atients	3,"
		Cancer Resea	irch 48:405.	<u>3-4058, 19</u>	88.		1.6		
	ок	Sastry et al.,	'Cloning of	the immun	ological repertoire in	Escherichi	<i>a coli</i> for g	enerati	on of
			monoclonal catalytic antibodies: Construction of a heavy chain variable region-s						
	-				ci. USA 86:5728-5732		17) 1001 6		
	OL	Shitara et al.,	Applicatio	n or Anti-S	Sialyl Lea Monoclonal	antibody,	KM231, fo	r	
F37.43.43.43		Immunothera	py of Cance	r," Anticar	cer Res. 11:2003-201			<u>-</u> .	
EXAMINE	K				DATE CONSIDERED)			
* 12 V A 3 413 11	D								
* EXAMINI					nformance with MPEP 609. Drawith next communication to apple	_	citation if not in		
		omormance and not const	acica. include co	FY or one roun	man next communication to app	neam(s).			

EXPRESS	WAII	. NO. EV336652038	US		Sheet <u>16</u> of <u>17</u>					
FORM PTO-144	9	U.S.	DEPARTMENT OF	COMMERCE	ATTY. DOCKET NO.	Al	PLICATION NO.			
(REV.7-80)		PAT	ENT AND TRADE	MARK OFFICE	400068.413	1	0/601,080			
[APPLICANTS					
INF	ORM	ATION DISCLOSU	RE STATEM	ENT	John L. Magnani et a	al				
		(Use several sheets if nec	essary)		FILING DATE		OUP ART UNIT			
					June 19, 2003	1	545			
			.		1,0000					
			U.S.	. PATENT	DOCUMENTS					
*EXAMINER INITIAL		DOCUMENT NUMBER	DATE		NAME	CLASS	SUBCLASS		DATE OPRIATE	
	PA									
			FORE	GN PATE	NT DOCUMENTS				-	
TPE		DOCUMENT	DATE		COUNTRY	 -		TRANS	LATION	
11.5	 	NUMBER	2.11.0		COOMING	<u> </u>		YES	NO	
	РВ									
N 1 3 2004	E C	ОТНЕ	R PRIOR A	RT (Including	Author, Title. Date, Pertinent P	ages, Etc.)				
34	7	Siuzdak et al	"Examina	tion of the	Sialyl Lewis X – Calc	um Com	plex By Elec	ctrospr	av	
TRADEMARK	PC				Medicinal Chemistry					
		Stanley and A	Atkinson, "T	he LEC11	Chinese Hamster Ova	ry Mutan	Synthesize	s N-Lii	nked	
	PD	Carbohydrate	es Containin	g Sialylate	d, Fucosylated Lactosa	mine Un	ts. Analysi	s By O	ne-	
	ļ	and Two-Dir	nensional H	NMR Spe	ctroscopy," J. Biol. Ch	em. 263(:	23):11374-1	1381,	1988.	
	PE				ction of highly efficien		satile set of	mamm	alian	
	1.0	expression v	ectors," Nuc	leic Acids I	Research. 17:7110, 19	89.	- C - V 1	A 11.		
	PF				nd Functional Charact					
		107: 1853-18		noming in	to Peripheral Lymph N	vodes, J	ournai oj Ce	и вюн	ogy	
	 	Stroud et al	"Extended"	Type 1 Cha	in Glycosphingolipids	· Dimerio	· Le (III ⁴ V ⁴	Fuede	() ac	
	PG	Human Tum	or-associate	d Antigen '	' J. Biol. Chem. 266(13	3)·8439-8	446 1991	i uczec	6) 43	
		Svenson and	Lindberg. "	Coupling o	f Acid Labile Salmone	ella Speci	fic Oligosac	charide	es to	
	PH	Macromolec	ular Carriers	s," J. Immu	nol. Meth. 25:323-335	, 1979.				
	l	Takada et al.	, "Adhesion	of Human	Cancer Cells to Vascu	lar Endot	helium Med	liated b	y a	
	PI	Carbohydrate	e Antigen, S	ialyl Lewis	A ¹ ," Biochem. Bioph	ys. Res. C	ommun. 17	9(2):71	3-	
	<u> </u>	719, 1991.								
	PJ				lar family essential for		cell-cell ad	hesion	and	
	''				<u>net. 3(8):213-217, 198</u>					
	PK	Thoma, G. et Chem. Int. E.			ole, Highly Potent E-So	electin Ai	ntagonist," A	Ingew.		
		Chem. Im. Di	a. 10(1)j. J	J.1 JUT1, 1	2001.					
		Tilton, R.G	"Exdontoxi	n-Induced	Leukocyte Accumulati	on in Aa	ueous Fluid	of Rate	sis	
	PL	Decreased by	a Small Mo	olecule Sel	le Selectin," İnvestigative Opthalmology & Visual Science					
					227, February 15, 1996.					
EXAMINE	ER				DATE CONSIDERED					

* EXAMINER: Initial if reference considered, whether or not criteria is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant(s).

EATRESS	VIAIL	7 NO. E V 330032036	<u> </u>				Sheet 17	UL <u>17</u>		
FORM PTO-1449)		DEPARTMENT OF		ATTY, DOCKET NO.	APP	LICATION NO.			
(REV.7-80)		PAT	ENT AND TRADE	MARK OFFICE	400068.413	10/	601,080			
					APPLICANTS					
INFO	ORM	ATION DISCLOSU	RE STATEM	ENT	John L. Magnani et a	ıl				
		(Use several sheets if nec	cessary)		FILING DATE	GRO	UP ART UNIT	_		
					June 19, 2003	164	45			
			U.S	. PATENT	DOCUMENTS	•	- "			
*EXAMINER		DOCUMENT NUMBER	DATE		NAME	CLASS	SUBCLASS		G DATE OPRIATE	
TPE Y	ΩA									
	187 			<u> </u>		1	<u> </u>	I		
JAN 1 3 2004	Q Q		FORE	IGN PATE	NT DOCUMENTS					
3	Š	DOCUMENT NUMBER	DATE		COUNTRY				LATION	
& TOANESTO	<u> </u>	Nomber						YES	NO	
" PALIE.	QB							<u> </u>		
		ОТНЕ	ER PRIOR A	RT (Including	g Author, Title, Date, Pertinent Pa	iges, Etc.)				
					etween daunorubicin ar				erum	
	QC				ises, as required for a ly					
		conjugate: In	n vitro and i	<i>n vivo</i> stud	ies," Proc. Natl. Acad.	Sci. USA	79:626-629), 1982		
	QD	Tyrrell et al., Natl. Acad. S			nts for the carbohydrate 76, 1991.	e ligand of	E-selectin	," Proc	•	
	QE	Walz et al., " Tumor Cells			I-1 of the Sialyl-Le ^X De	eterminant	on Myeloi	d and		
	QF	Ward and M	ulligan, "Blo	ocking of a	of adhesion molecules in vivo as anti-inflammatory					
	Ųr	therapy," Imi	munology 1:	165-171, 1	1994.	D II	<u> </u>		-	
	QG	Whisler and	Yates, "Reg	ulation of I	Lymphocyte Responses	By Huma	n Ganglios	sides.	l. ~1 ~£	
	Ì	Immunology	125(5):2106	5-2111, 198	and the Induction of It 30.	_				
	0,,	Zhou et al., "	The Selecting	n GMP-140	Binds to Sialylated, F	ucosylated	l Lactosam	inogly	cans	
	QH	on Both Mye	cloid and No	nmyeloid (Cells," Journal of Cell	Biology 1 I	5(2):557-5	<u>664, 19</u>	<u>91.</u>	
	QI	Zopt et al., ". Derivatives (Affinity Pur Coupled to S	itication of Sepharose,"	Antibodies Using Olig Meth. Enzymol. 50:17	gosacchari 1-175, 197	de-Pheneth 8.	ıylamır	ie	
	QJ									
	QK									
	QL									
EXAMINE	[]				DATE CONCIDEDED					
	c.r.				DATE CONSIDERED					
* EXAMIN	ER:	Initial if reference conside	red, whether or no	ot criteria is in co	onformance with MPEP 609. Drav	w line through o	itation if not in			

conformance and not considered. Include copy of this form with next communication to applicant(s).